Cargando…

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study

SUMMARY: Previous studies evaluated the association between proton pump inhibitor (PPI) use and subsequent fracture risk, but they showed ambiguous results. Therefore, the objective was to evaluate this association in a different study population. Our findings show that there is probably no causal r...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouwels, S., Lalmohamed, A., Souverein, P., Cooper, C., Veldt, B. J., Leufkens, H. G., de Boer, A., van Staa, T., de Vries, F.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034906/
https://www.ncbi.nlm.nih.gov/pubmed/20585937
http://dx.doi.org/10.1007/s00198-010-1337-8
_version_ 1782197701426806784
author Pouwels, S.
Lalmohamed, A.
Souverein, P.
Cooper, C.
Veldt, B. J.
Leufkens, H. G.
de Boer, A.
van Staa, T.
de Vries, F.
author_facet Pouwels, S.
Lalmohamed, A.
Souverein, P.
Cooper, C.
Veldt, B. J.
Leufkens, H. G.
de Boer, A.
van Staa, T.
de Vries, F.
author_sort Pouwels, S.
collection PubMed
description SUMMARY: Previous studies evaluated the association between proton pump inhibitor (PPI) use and subsequent fracture risk, but they showed ambiguous results. Therefore, the objective was to evaluate this association in a different study population. Our findings show that there is probably no causal relationship between PPI use and hip fracture risk. INTRODUCTION: Previous studies evaluated the association between PPI use and subsequent fracture risk, but they showed ambiguous results. To further test these conflicting results, the objective of this study was to evaluate the association between the use of PPIs and the risk of hip/femur fracture in a different study population. METHODS: A case-control study was conducted using data from the Dutch PHARMO record linkage system. The study population included 6,763 cases aged 18 years and older with a first hip/femur fracture during enrolment and 26,341 age-, gender- and region-matched controls. RESULTS: Current users of PPIs had an increased risk of hip/femur fracture yielding an adjusted odds ratio (AOR) of 1.20 (95% CI 1.04–1.40). Fracture risk attenuated with increasing durations of use, resulting in AORs of 1.26 (95% CI 0.94–1.68) in the first 3 months, 1.31 (95% CI 0.97–1.75) between 3 and 12 months, 1.18 (95% CI 0.92–1.52) between 13 and 36 months and 1.09 (95% CI 0.81–1.47) for use longer than 36 months. CONCLUSION: Our findings show that there is probably no causal relationship between PPI use and hip fracture risk. The observed association may be the result of unmeasured distortions: although current use of PPIs was associated with a 1.2-fold increased risk of hip/femur fracture, the positive association was attenuated with longer durations of continuous use. Our findings do not support that discontinuation of PPIs decreases risk of hip fracture in elderly patients.
format Text
id pubmed-3034906
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-30349062011-03-16 Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study Pouwels, S. Lalmohamed, A. Souverein, P. Cooper, C. Veldt, B. J. Leufkens, H. G. de Boer, A. van Staa, T. de Vries, F. Osteoporos Int Original Article SUMMARY: Previous studies evaluated the association between proton pump inhibitor (PPI) use and subsequent fracture risk, but they showed ambiguous results. Therefore, the objective was to evaluate this association in a different study population. Our findings show that there is probably no causal relationship between PPI use and hip fracture risk. INTRODUCTION: Previous studies evaluated the association between PPI use and subsequent fracture risk, but they showed ambiguous results. To further test these conflicting results, the objective of this study was to evaluate the association between the use of PPIs and the risk of hip/femur fracture in a different study population. METHODS: A case-control study was conducted using data from the Dutch PHARMO record linkage system. The study population included 6,763 cases aged 18 years and older with a first hip/femur fracture during enrolment and 26,341 age-, gender- and region-matched controls. RESULTS: Current users of PPIs had an increased risk of hip/femur fracture yielding an adjusted odds ratio (AOR) of 1.20 (95% CI 1.04–1.40). Fracture risk attenuated with increasing durations of use, resulting in AORs of 1.26 (95% CI 0.94–1.68) in the first 3 months, 1.31 (95% CI 0.97–1.75) between 3 and 12 months, 1.18 (95% CI 0.92–1.52) between 13 and 36 months and 1.09 (95% CI 0.81–1.47) for use longer than 36 months. CONCLUSION: Our findings show that there is probably no causal relationship between PPI use and hip fracture risk. The observed association may be the result of unmeasured distortions: although current use of PPIs was associated with a 1.2-fold increased risk of hip/femur fracture, the positive association was attenuated with longer durations of continuous use. Our findings do not support that discontinuation of PPIs decreases risk of hip fracture in elderly patients. Springer-Verlag 2010-06-29 2011 /pmc/articles/PMC3034906/ /pubmed/20585937 http://dx.doi.org/10.1007/s00198-010-1337-8 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
Pouwels, S.
Lalmohamed, A.
Souverein, P.
Cooper, C.
Veldt, B. J.
Leufkens, H. G.
de Boer, A.
van Staa, T.
de Vries, F.
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
title Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
title_full Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
title_fullStr Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
title_full_unstemmed Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
title_short Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
title_sort use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034906/
https://www.ncbi.nlm.nih.gov/pubmed/20585937
http://dx.doi.org/10.1007/s00198-010-1337-8
work_keys_str_mv AT pouwelss useofprotonpumpinhibitorsandriskofhipfemurfractureapopulationbasedcasecontrolstudy
AT lalmohameda useofprotonpumpinhibitorsandriskofhipfemurfractureapopulationbasedcasecontrolstudy
AT souvereinp useofprotonpumpinhibitorsandriskofhipfemurfractureapopulationbasedcasecontrolstudy
AT cooperc useofprotonpumpinhibitorsandriskofhipfemurfractureapopulationbasedcasecontrolstudy
AT veldtbj useofprotonpumpinhibitorsandriskofhipfemurfractureapopulationbasedcasecontrolstudy
AT leufkenshg useofprotonpumpinhibitorsandriskofhipfemurfractureapopulationbasedcasecontrolstudy
AT deboera useofprotonpumpinhibitorsandriskofhipfemurfractureapopulationbasedcasecontrolstudy
AT vanstaat useofprotonpumpinhibitorsandriskofhipfemurfractureapopulationbasedcasecontrolstudy
AT devriesf useofprotonpumpinhibitorsandriskofhipfemurfractureapopulationbasedcasecontrolstudy